A galectina-1 (Gal-1) é uma lectina que reconhece ?-galactosídeos e participa de vários processos biológicos, incluindo a modulação da resposta inflamatória. Dados da literatura mostram a participação desta lectina na indução da exposição de fosfatidilserina (FS - um marcador de apoptose), na geração de espécies reativas do oxigênio (EROs) e na modulação quimiotática de neutrófilos. Entretanto, ainda são escassos os dados relacionados ao impacto biológico da Gal-1, exógena e endógena, sobre a biologia destas células. Neste trabalho foram avaliados, in vitro, alguns aspectos funcionais da interação Gal-1/neutrófilo. Determinou-se o nível de expressão da Gal-1 (Western Blotting) e de seu mRNA (PCR real time), em leucócitos humanos obtidos do sangue periférico de doadores sadios e em células da linhagem promielocítica humana (HL-60). Leucócitos do sangue periférico e células HL-60 não expressam níveis detectáveis da proteína e também do mRNA para Gal-1. Por meio de ensaios de quimiluminescência (QL) foi possível analisar a capacidade da Gal-1 recombinante humana de induzir e modular a produção de EROs em neutrófilos humanos não ativados e ativados com fMLP (n-Formil-Methionyl-Leucyl-Phenylalanine). A Gal-1 induz a produção de EROs de modo dose-dependente em neutrófilos ativados com fMLP. Entretanto, em neutrófilos não ativados esta lectina não induz o metabolismo oxidativo e, além disso, é capaz de modular negativamente a produção de EROs em resposta ao fMLP. Tanto nas células não ativadas quanto ativadas com fMLP, os efeitos da Gal-1 na produção de EROs estão parcialmente associados a sua propriedade lectínica. Na literatura ainda não há relatos sobre a interferência da Gal-1 no metabolismo oxidativo em neutrófilos ativados com repetidas doses de fMLP. Sabe-se que o tratamento sucessivo com fMLP reduz os níveis de produção de EROs por neutrófilos, no entanto, a presença de Gal-1 não interferiu neste processo. Interessantemente, neutrófilos recuperados do peritônio de camundongos Gal-1-/- liberam mais EROs em resposta ao fMLP e a Gal-1 exógena quando comparado aos neutrófilos de animais selvagens. Com base nos achados in vitro e sabendo que na sepse polimicrobiana o neutrófilo desempenha um papel importante, o próximo passo foi utilizar o modelo de M-CLP (sepse moderada) em camundongos destituídos (Gal-1-/-) ou não (Gal-1+/+) do gene da Gal-1. Animais Gal-1-/-, apresentam menor taxa de sobrevivência. O influxo de neutrófilos e a carga bacteriana no peritônio são maiores nos animais Gal-1-/- apesar da menor quantidade de bactérias detectadas no sangue, em relação aos animais selvagens. No pulmão, o influxo de neutrófilos é semelhante para ambos os grupos. No entanto, após a injeção intraperitoneal de 107 Unidades Formadoras de Colônias (UFC) de bactérias, camundongos Gal-1-/- apresentam maior atividade bactericida no lavado peritoneal e sangue, em relação aos selvagens. A participação da Gal-1 na homeostase de neutrófilos foi demonstrada in vitro, por citometria de fluxo (anexina-V-FITC), onde a indução de FS nos neutrófilos tratados com Gal-1 favoreceu a fagocitose destas células por macrófagos. Portanto, este conjunto de resultados sugere que a Gal-1, exógena ou endógena, pode modular funções imunológicas de neutrófilos e participar da regulação do processo inflamatório/infeccioso sistêmico. / Galectin-1 (Gal-1) is a lectin that recognizes ?-galactosides and participates in biological processes, including modulation of the inflammatory response. Literature data show the involvement of this lectin to induce exposure of phosphatidylserine (PS - a marker of apoptosis), in the generation of reactive oxygen species (ROS) and in modulation of neutrophil chemotaxis. However, there are few data related to the biological impact of exogenous and endogenous Gal-1 on the biology of these cells. This study evaluated, in vitro, some functional aspects of the interaction of Gal-1 and neutrophil. It was determined the expression level of Gal-1 (Western blotting) and its mRNA (real time PCR) on human leukocytes obtained from peripheral blood of healthy donors and human promyelocytic cell line (HL-60). Peripheral blood leukocytes and HL-60 cells do not express detectable levels of this protein as well as the Gal-1 mRNA. Through chemiluminescence testing (CL) it was possible to analyze the ability of recombinant human Gal-1 to induce and modulate the production of ROS in naïve and activated (n-Formyl-Methionyl-Leucyl-Phenylalanine-fMLP) human neutrophils. Gal-1 induces ROS production in a dose-dependent way in fMLP activated neutrophils. However, in naive neutrophils this lectin does not induce oxidative stress and can negatively modulate ROS production in response to fMLP. The effects of Gal-1 on ROS production in both non-activated cells and activated cells are partially associated with their lectin property. In the literature there are no data about the interference of Gal-1 on ROS production in activated neutrophils with repeated doses of fMLP. It is known that the subsequent treatment with fMLP reduced levels of ROS production by neutrophils; however, the presence of Gal-1 did not affect this process. Interestingly, peritoneum neutrophils from Gal-1-/- mice release more ROS in response to fMLP and exogenous Gal-1 when compared to neutrophils from wild type animals. Based on the in vitro findings and considering that in polymicrobial sepsis, neutrophils play an important role, the next step was to use the M-CLP model (moderate sepsis) in mice lacking (Gal-1-/-) or not (Gal-1+/+) Gal-1 gene. Gal-1-/- animals present lower survival rate and fewer bacteria in the blood despite having higher bacterial load in infectious focus in relation to wild type mice. The rates of neutrophils influx into the peritoneum and lungs are similar for both groups. The participation of Gal-1 in the homeostasis of neutrophils was demonstrated in vitro by flow cytometry (annexin V-FITC), where induced PS by Gal-1 in the neutrophils enhanced the phagocytosis of these cells by macrophages. Therefore, this set of results suggests that Gal-1, exogenous or endogenous, can modulate immune functions of neutrophils and participate in the regulation of inflammatory/infectious disorders.

A galectina-1 (Gal-1) é uma proteína que reconhece ?-galactosídeos e participa de vários processos biológicos, incluindo a modulação da resposta imunológica. Vários relatos da literatura reportam o potencial uso terapêutico da Gal-1 para doenças auto-imunes, inflamatórias e infecciosas. Entretanto, são escassos os relatos sobre o envolvimento da Gal-1 na infecção causada por Tripanosoma cruzi. Neste trabalho foi avaliada a participação da Gal-1 endógena e a administração de Gal-1 exógena na evolução da infecção aguda induzida experimentalmente por T. cruzi. Foram realizados experimentos in vivo e/ou in vitro com o uso de Gal-1 recombinante humana, camundongos C57BL/6 deficientes do gene da Gal-1 (Gal-1 KO, knock-out) ou do gene Toll Like Receptor 4 (TLR-4 KO, knock-out) e selvagens (WT, wild type), além de seus macrófagos. A forma de T. cruzi utilizada foi a tripomastigota da cepa Y. Os parâmetros analisados na caracterização do processo de infecção foram: i) parasitemia e sobrevivência de animais; ii) histopatologia do tecido cardíaco; iii) imunofenotipagem de leucócitos; iv) dosagem de citocinas; v) determinação de taxas de invasão e liberação de parasitas a partir de células infectadas; vi) produção de óxido nítrico por macrófagos. A Gal-1 e/ou anticorpos anti-glicopeptídeos miméticos de mucina de T. cruzi ligam-se à glicanas da superfície deste parasita e impedem sua invasão em fibroblastos e sua captura por macrófagos. O tratamento de macrófagos infectados com Gal-1 reduz a liberação de parasitas e aumenta a produção de óxido nítrico (NO) por um mecanismo, aparentemente, independente da sinalização via TLR-4. Os camundongos KO Gal-1 e os WT tratados com Gal-1 exógena apresentaram as menores taxas de parasitemia, sendo que os primeiros são mais resistentes à infecção aguda por T. cruzi. A ausência da Gal-1 endógena nos animais infectados provocou vários efeitos como a redução no infiltrado inflamatório e carga parasitária no tecido cardíaco, níveis séricos elevados de citocinas (IL-2, IL-4, IL-6, IL-10 e IL-17A), menor porcentagem de linfócitos T CD4+ e maior de T CD8+ no coração dos animais, aumento do influxo de neutrófilos na cavidade peritoneal e no coração. Com base nesse conjunto de resultados sugerimos que a ausência de Gal-1 endógena ou o tratamento de animais com Gal- 1 exógena promoveram perfis imunológicos (resposta inata e adaptativa) favorecedores da resolução da infecção experimental aguda por T. cruzi / Galectin-1 (Gal-1) is a protein that recognizes ?-galactosides and participates in many biological processes, including the modulation of the immune response. Several reports in the literature show the potential therapeutic use of Gal-1 to autoimmune, inflammatory and infectious diseases. However, there are few reports on the involvement of Gal-1 on infection caused by Trypanosoma cruzi. Here, we evaluated the involvement of endogenous Gal-1 and Gal-1 administration of exogenous in the development of acute experimental infection by T. cruzi. Recombinant human Gal-1, C57BL/6 mice deficient for Gal-1 gene (Gal-1 KO, knockout) or for Toll like receptor 4 gene (TLR-4 KO, knock-out) or C57BL/6 wild type mice (WT), and macrophages from these animals were used in experiments in vivo and / or in vitro. The form of T. cruzi used in this work was trypomastigotes from Y strain. The analyzed parameters characterizing the process of infection were: i) parasitemia and survival of animals; ii) histopathology of cardiac tissue; iii) leucocyte immunophenotyping; iv) cytokine assay; v) determination of invasion and release rates of parasites from infected cells; vi) nitric oxide production by macrophages. The Gal-1 and / or antibodies anti- glycopeptides that mimics T. cruzi mucin bind to glycans on the surface of this parasite and prevent invasion of the parasite in fibroblasts and its capture by macrophages. Treatment of infected macrophages with Gal-1 promotes a lower release of parasites and increased production of nitric oxide (NO) by these phagocytes, and this production of NO is independent of TLR-4 signaling pathway. The Gal-1 KO mice and WT mice treated with exogenous Gal-1 had the lowest rates of parasitemia and the first group is more resistant to acute infection with T. cruzi. The absence of endogenous Gal-1 in infected animals caused various effects such as a reduction in the inflammatory infiltrate and the parasite load in the cardiac tissue, elevated serum levels of cytokines (IL-2, IL-4, IL-6, IL-10 and IL- 17A), a lower percentage of T CD4+ and increased T CD8+ the hearts of animals, increased influx of neutrophils into the peritoneal cavity and heart tissue. Based on this set of results we suggest that the absence of endogenous Gal-1 or treatment of animals with exogenous Gal-1 promoted immunological profiles (innate and adaptive response) favoring the resolution of acute experimental T. cruzi infection.

High grade gliomas remain a devastating disease, for which a curative therapy is virtually absent. The high medical need is unmet by novel treatment strategies and advances in chemo-and radiotherapy. Patients diagnosed for GBM face a median survival of 15 months after maximal standard-of-care therapy, and relapse is often observed due to micro-metastasis in the direct environment of resection. In part, current treatment modalities such as chemo-and immunotherapy are hampered in their efficacy due to the specialized TME. This area is adequately equipped to withstand the cytotoxic attack of chemo- and immunotherapy. Therefore, we hypothesized that modulation of the TME could decrease these defense mechanisms, and increase susceptibility to tumor lysis.In this respect, we focused on Gal-1 as an ideal target to modulate the TME in the context of GBM. Gal-1 exerts multiple tumor promoting functions. From pre-clinical research, we have learned that Gal-1 is an important mediator for the proliferation and migration of tumor cells, moreover Gal-1 could also promote angiogenesis in the TME, providing nutrients and oxygen for GBM to grow. Gal-1 also maintains the inherent defense mechanisms to chemo and immunotherapy. Gal-1 is crucial for the resistance mechanisms to TMZ by altering the EPR stress response. Moreover, and most important for our purposes, Gal-1 is also a crucial immune suppressor in the TME, which can induce apoptosis in activated T cells, and recruit Tregs. To target Gal-1 in the TME would be clinically most relevant if this could be performed via a non-invasive treatment modality. Therefore, we developed a nanoparticle complex that could deliver siGal-1 from the nasal cavity directly to the CNS, and even the TME. This nose-to-brain delivery bypasses systemic routes, with a higher (and more selective) local bioavailability in the CNS. The major pharmaceutical excipient in this nanoparticle complex consists of chitosan polymers. These polymers are highly interesting agents to promote nose-to-brain delivery due their muco-adhesive and epithelial barrier modulation properties. When applying these particles in vitro on GBM cells, a solid decrease of Gal-1 was noted, and the epithelial modulatory properties were confirmed. Furthermore, we observed a rapid transport from the nasal cavity to the brain upon intranasal administration of a highly-concentrated chitosan nanoparticle siGal-1 suspension and we could even observe the sequence-specific cleavage of Gal-1 mRNA, and a decrease of Gal-1 in the TME. This Gal-1 reduction could modulate the TME from immune suppression to immune activation, as demonstrated by decrease in suppressor cells, and increased stage of activation in rejective immune cells. Moreover, due to decreased Gal-1, also angiogenesis was alleviated, and a reduced size in vasculature was observed, mimicking a morphological vessel normalisation. Reversing the immune and vascular contexture of the TME by Gal-1 reduction seemed a prerequisite to increase the efficacy of TMZ, DC vaccination and PD-1 blocking. In combination experiments, we noticed that siGal-1 on top of these treatments, could further increase the efficiency of chemo and immunotherapy. The findings presented in this thesis can serve as a proof of concept for the feasibility to modulate and re-orchestrate the TME of GBM via intranasal administration. The intranasal administration of siGal-1 could represent a valuable clinically translational treatment to increase the efficiency of chemo- and immunotherapy for GBM patients. In our research facilities, a phase 0 as a first-in-human trial is actively pursued. / Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie) / info:eu-repo/semantics/nonPublished

Muscular dystrophies are a heterogeneous group of genetic diseases that involve mutations in genes leading to progressive muscular weakness. Limb-Girdle Muscular Dystrophy 2B (LGMD2B) is a subset of muscular dystrophy caused by mutations in the DYSF gene, which encodes for dysferlin protein and has an incidence of 1/100,000-1/200,000 people, or 1/300 people of Libyan Jewish descent. Since there is no effective treatment that can cure or reverse effects of LGMD2B once diagnosed, our goal is to investigate and develop a protein therapy that mitigates effects of this disease in patients. Galectin-1 (Gal-1) is a small, soluble 14.5 kDa protein with a carbohydrate recognition domain capable of stabilizing the sarcolemma. The exact role that Gal-1 plays in myogenic cells is not fully understood, however, it is known that Gal-1 possesses anti-inflammatory properties and increases the terminal differentiation of committed myogenic cells. Our hypothesis is that Gal-1 treatment increases myogenic potential, improves membrane repair capability, and modulates the immune response in models of LGMD2B by stabilizing muscle integrity, leading to decreased disease manifestation. To test this hypothesis and assess the effect of Gal-1 treatment on myogenesis, anti-inflammatory modulation, and membrane repair, we designed, produced, and purified recombinant human galectin-1 (rHsGal-1) to be used in LGMD2B models. Our in vitro results indicate that after 2-3 days of treatment with 0.11μM rHsGal-1, A/J-/- myotubes enhance expression of myogenic late markers and increase in size and alignment. Additionally, after short-term treatment, rHsGal-1 improves membrane repair capability in a Ca2+ independent manner through an activated carbohydrate recognition domain (CRD) in in vitro and in vivo models of LGMD2B. We give evidence that rHsGal-1 upregulates anti-inflammatory cytokines, increases functional activity, and modulates the canonical NF-κB inflammatory pathway in dysferlin-deficient models by decreasing expression of TAK-1 and the p65 and p50 subunits in vitro and short-term in vivo treatment. Similar effects of the rHsGal-1 treatment were observed in patient-derived dysferlin-deficient human myotubes. Exploratory results show a potential decrease in muscle fat deposition in Bla/J mice. Furthermore, Gal-1 contributes to immune modulation by helping to initiate muscle regeneration by shifting M2 macrophage polarization. Together, our novel discoveries provide direct evidence that Gal-1 is a promising candidate to treat LGMD2B disease pathologies by improving expression of late-stage myogenic markers, improving membrane repair in vitro and short-term in vivo studies, promoting muscle regeneration through immune modulation, and reducing canonical NF-κB inflammation.

No description available.

A galectina-1 (Gal-1) é uma lectina homodimérica multifuncional capaz de reconhecer e se ligar a beta-galactosídeos por meio de um domínio denominado carbohydrate recognition domain (CRD). A Gal-1 humana (Gal-1h) e a Gal-1 de camundongo (Gal-1c) mantêm 88,15% de homologia e, apesar de não existirem mutações em aminoácidos-chave do CRD, há substituições próximas a esses resíduos. Considerando as implicações dessas diferenças em estrutura e função, e que é comum a utilização de modelos murinos para estudar a função Gal-1, o presente trabalho objetiva analisar comparativamente a Gal-1c e a Gal-1h por meio de ensaios de cristalização e determinação estrutural da Gal-1c, além da avaliação comparativa da atividade lectínica da Gal-1h e da Gal-1c por glycan array e hemaglutinação. Também foi avaliada a capacidade de ambas as Gal-1 em induzir a exposição de fosfatidilserina (FS) em neutrófilos ativados provenientes de medula de camundongos normais ou deficientes de ?-2 integrina (Mac-1), de modo a investigar se a interação Gal-1/Mac-1 estaria envolvida nesse processo. Preparações homogêneas e ativas de Gal-1c e Gal-1h foram utilizadas nos ensaios. Os cristais de Gal-1c foram obtidos em 20% de polietilenoglicol 3350 e 0,2 M de fluoreto de amônio. Os dados de difração de raios X foram coletados e processados, obtendo-se uma estrutura com resolução de 2,4 Å. Observou-se que substituições de aminoácidos entre a Gal-1c e a Gal-1h estão localizadas em regiões expostas ao solvente, próximas do CRD e distantes da interface de dimerização. A análise comparativa entre Gal-1c e Gal-1h mostrou que estas substituições conferem a Gal-1c um caráter mais polar, com consequente aumento da distribuição de volume molecular. Nos ensaios de hemaglutinação, pode-se observar que é necessária uma concentração 2 vezes maior de Gal-1c para aglutinar eritrócitos humanos, de carneiro e de coelho na mesma proporção que a Gal-1h. Por meio do glycan array, pode-se determinar o perfil de ligação a glicanas de ambas as Gal-1. As duas Gal-1 apresentam afinidade por glicanas ramificadas contendo galactose terminal, e a Gal-1h apresentou maior intensidade de ligação às glicanas quando comparada à Gal-1c. Preparações de Gal-1c e Gal-1h induzem níveis semelhantes de exposição de FS na superfície de neutrófilos deficientes ou não de Mac-1, sugerindo que a interação Gal-1/Mac-1 não esteja envolvida no processo de exposição de FS na superfície de neutrófilos ativados. Assim, a diferença sequencial entre a Gal-1c e a Gal-1h é capaz de gerar diferenças estruturais consideráveis que implicam no reconhecimento diferencial de glicanas, o que, entretanto, não se reflete na capacidade de indução de FS na superfície de neutrófilos ativados. Além disso, a interação Gal-1/Mac-1 parece não participar desse processo, o que pode indicar que o papel da Gal-1 no turnover de neutrófilos, via reconhecimento fagocítico, seja um processo complexo e independente dessa interação. / Galectin-1 (Gal-1) is a homodimeric and multifunctional lectin that recognizes and binds to beta-galactoside by a carbohydrate recognition domain (CRD). Human Gal-1 (hGal-1) and mouse Gal-1 (mGal-1) are 88.15% identical, and although there are no mutations in key amino acids within the CRD, there are differences in the amino acids sequence near the CRD. Given the potential of these differences to alter overall structure and function, and the common utilization of murine models to study Gal-1 function, we sought to directly compare key biochemical features of hGal and mGal-1. Thus, we performed crystallization and structure determination assays of mGal-1, and determined the carbohydrate binding specificy of mGal-1 and hGal-1 using a glycan array and using hemagglutination assay. We also evaluated the ability of both Gal-1 to induce exposure of phosphatidylserine (PS) in activated neutrophils from the bone marrow of normal or ?-2 integrin (Mac-1) deficient mice, in order to investigate the involvement of Gal-1/Mac-1 interaction in this process. To accomplish this, homogeneous and active preparations of hGal-1 and mGal-1 were used in the study. mGal-1 crystals were obtained in 20% polyethylene glycol 3350 and 0.2 M ammonium fluoride. Data from X-ray diffraction were collected and processed, yielding a structure with a final resolution of 2.4 Å. The amino acid substitutions found between mGal-1 and hGaI-1 are detected on the solvent-exposed surfaces where the CRDs are located and not on the proteins dimerization surfaces. A comparative structural analysis between mGal-1 and hGal-1 shows that these amino acid substitutions confer to mGal-1 a greater number of ionizable residues, polar character, appearance of the acid regions clustered, and a slight increase of volume distribution. In hemagglutination assays, twice the concentration of mGal-1 was required to cause equivalent agglutination of human, sheep or rabbit erythrocytes as hGal-1. Glycan array analysis demonstrated that both galectins have affinity for branched glycans containing terminal galactose residues. However, hGal-1 appeared to display higher levels of binding that mGal-1. Preparations of mGal-1 and hGal-1 induced similar levels of PS exposure on normal or Mac-1 deficient neutrophils, suggesting that the interaction Gal-1/Mac-1 is not involved in this process. Thus, hGal-1 and mGal-1 appear to possess considerable differences in glycan recognition that likely reflects subtle difference in amino acid sequence. Furthermore, the interaction Gal-1/Mac-1 do not appear to participate in this PS exposure process, which suggest that other Gal-1 receptors are likely important in this process.

A galectina-1 (Gal-1) pertence a uma família de lectinas endógenas que reconhecem ß-galactosídeos e atuam em vários processos biológicos. A Gal-1 pode modular a resposta imunológica por vários mecanismos incluindo o controle da liberação de citocinas pró e anti-inflamatórias e o direcionamento dessa resposta para um padrão do tipo TH2. Apesar da Gal-1 participar de vários processos fisiopatológicos, na literatura não existe relatos sobre o papel dessa lectina em infecções fúngicas. O objetivo deste trabalho foi investigar o impacto biológico da Gal-1 no modelo experimental de histoplasmose murina. Os camundongos (Gal-1-/- e Gal-1+/+) foram inoculados, por via intratraqueal, com uma carga fúngica sub-letal (5x105 leveduras) e a sobrevida desses animais foi avaliada até o 30o dia de infecção. Considerando que o início da mortalidade dos animais ocorreu após duas semanas de infecção, as demais análises foram realizadas em amostras obtidas no 15o dia. O grau de disseminação do H. capsulatum foi analisado pela contagem do número de unidades formadoras de colônia, em partes de pulmões ou baços dos animais infectados. Os cortes de pulmões foram corados por hematoxilina eosina ou por prata (GMS), para investigação histopatológica e quantificação de neutrófilos ou fungos, respectivamente. Nos fluídos bronco-alveolares (BAL) foram realizadas contagens globais e diferenciais de leucócitos. As dosagens de citocinas e de prostagladina E2 foram feitas por ELISA, em homogeneizados de pulmões. A coloração por tetróxido de ósmio foi usada na avaliação da capacidade da Gal-1 de induzir ou modular a formação de corpúsculos lipídicos, in vitro, por componentes do fungo. Nos soros dos animais de experimentação foi determinada a concentração total de nitrito, como indicador da produção de óxido nítrico. A análise dos resultados de sobrevivência indicou que 100% dos animais Gal-1+/+ resistiram à infecção por H. capsulatum; ao contrário, apenas 33% dos animais Gal-1-/- sobreviveram. Os números médios de unidades formadoras de colônias recuperadas no pulmão e no baço de camundongos Gal-1-/- foram de 2,7 e 3,8 vezes maiores do que os obtidos de animais Gal-1+/+, respectivamente. De modo semelhante, os números médios de neutrófilos e fungos no pulmão de animais Gal-1-/-, foram superiores aos valores encontrados nos pulmões de animais grupo Gal-1+/+. Curiosamente, nos homogeneizados pulmonares dos e o dobro da concentração de nitrito total sérico. Além disso, nos homogeneizados de pulmão dos animais Gal-1desafiados com o fungo, detectou-se elevadas concentrações de citocinas do tipo T1 e inflamatórias (IFN-, IL-1 e IL-12) em comparação com amostras de animais selvagens. Em ensaios in vitro, esta lectina não foi capaz de induzir corpúsculos em células do lavado peritoneal de camundongos Gal-1e Gal-1, entretanto inibiu parcialmente a formação induzida por F1 e -glucana. Finalmente, sugerimos que a Gal-1 pode participar da montagem de uma resposta imunológica protetora contra o Histoplasma capsulatum, por modular a liberação de citocinas inflamatórias, síntese de eicosanóides, geração de óxido nitrito; e por controlar a migração e/ou as funções de leucócitos. Além disso, os dados obtidos desse trabalho poderão auxiliar no melhor entendimento da fisiopatologia da histoplasmose e no desenvolvimento de novas estratégias terapêuticas envolvendo o reconhecimento de carboidratos na resposta imunológica. / Galectin-1 (Gal-1) belongs an endogenous lectins family that recognizes -galactoside and participates of various biological activities. This lectin can modulate the innate and adaptative immune responses. Although, Gal-1 participates of various pathophysiological processes, in literature we did not find reports related to the participation of Gal-1 in fungal infections. The aim of this work was to investigate the biological impact of Gal-1 in the experimental histoplasmosis. The mice (GAL-1-/- and GAL-1+/+) were injected (i.t.) with 5 x 105 yeast cell and at 15 days post-infection, BALF cells and lungs cytokine and PGE2 were measured by ELISA. The Recovery of H. capsulatum was made in lung and spleen and the fungal burden was assessed as the CFU per organ. The lung slices were stained by hematoxiline eosin or with Gomoris methanemine silver (GMS) and submitted to histopathological investigation and quantification of neutrophil or fungus, respectively. Total and differential cell counts of the bronchoalveolar lavage (BAL).were performed using diluting solution in Neubauer chamber and Rosenfeld-stained smear. The capacity of Gal-1 to induce or modulate the lipids bodies formation by fungus components was analyzed by staining treated cells with osmium tetroxide. The total nitrite (NO2) concentration in the animals serum was measured by Griess reaction. All H. capsulatum-infected wild type mice survived until 30 days post-infection, whereas only 33% of the Gal-1-/- infected mice died during of this period of observation. At 15 days post-infection, CFU were found to be higher in the spleens or lung from infected-Gal1-/- mice. The number of neutrophils in the lung of the infected-Gal-1-/- mice higher than infected Gal-1+/+ animals. Curiously, H. capsulatum infected Gal-1-/- mice, presented higher levels of PGE2 and TH1 inflammatory cytokines (IFN-, IL-1 e IL-12) in comparison with wild type infected-mice. Adherent peritoneal cells peritoneal derived from Gal-1+/+ and Gal-1-/- mice and treated with Gal-1 did not induce lipid bodies. However, the capacity of F1 e -glucan to induce lipid bodies on the peritoneal cells was inhibited by gal-1 treatment. We suggest that the Gal-1 could participate of the development of a protective immune response to H. capsulatum.

Idiopathic Pulmonary Fibrosis (IPF) is a deadly disease of unknown origin, which causes 80,000 deaths every year in the US and Europe combined. Unknown etiology and late diagnosis, combined with limited treatment options, contribute to a dismal survival rate of 3-5 years post diagnosis. Although molecular mechanisms underlying IPF pathogenesis and progression have been studied for over two decades, lack of in vivo models that recapitulate chronic, progressive, and irreversible nature of IPF have contributed to limited therapeutic success in clinical trials. Currently, only two drugs, Pirfenidone and Nintedanib, are approved for IPF treatment in the US, with their efficacy yet to be completely determined. Patients with IPF often observe lung infections, alveolar collapse, and respiratory failure, which are associated with focal edema and local hypoxia and contribute to development of hypoxemia associated with acute exacerbation of IPF (AE-IPF). In my thesis, I posit that hypoxic injury to the lung epithelium can initiate profibrotic signaling that can contribute to pathogenesis and progression of pulmonary fibrosis in vitro and in vivo. In my in silico studies, I analyzed human protein kinases to identify structural peculiarities that diversify their functions and highlight central hub kinases governing cell signaling. Using this approach, I identified Focal Adhesion Kinase 1 (FAK1) as a central hub kinase contributing to cytoskeletal remodeling. My proteomics and transcriptional studies defined in vitro effect of hypoxia in activation of lung epithelial cells. Using systems biology approaches, I identified interplay between transforming growth factor – β (TGF–β) signaling, hypoxia signaling, and FAK1 signaling. Further, my studies identified Galectin-1 as a novel mediator of hypoxia-induced pulmonary fibrosis. To mimic exacerbation of PF in patients, I developed a novel mouse model of exacerbated pulmonary fibrosis using subclinical bleomycin injury with chronic hypoxia. Further, to fill the existing requirement of an in vivo model of chronic PF, I characterized a triple transgenic mouse model that conditionally activates hypoxia signaling in the lung epithelial cells and causes progressive PF over a span of 12 weeks. Lastly, I performed RNA-Seq experiments on primary AEC2s isolated from our transgenic mouse model to identify a hypoxia-mediated profibrotic role of microRNA-96 in down-regulation of PTEN, a tumor suppressor and anti-fibrotic protein. In conclusion, my studies established in vitro and in vivo roles of hypoxia in profibrotic activation of lung epithelium and identifies FAK1 and Gal-1 as key drivers of hypoxia-mediated fibrosis, which should be further evaluated in animal and human studies to determine their therapeutic potential.

Phosphorylation mediated inactivation of PTEN leads to multiple malignancies with increased severity. However, the consequence of such inactivation on downstream functions of PTEN are poorly understood. Therefore, the objective of my thesis is to ascertain the molecular mechanisms by which PTEN phosphorylation drives lung cancer. PTEN phosphorylation at the C-terminal serine/threonine cluster abrogates its tumor suppressor function. Despite the critical role of the PTEN C-tail in regulating its function, the crystal structure of the C-tail remains unknown. Using bioinformatics and structural analysis, I determined that the PTEN C-tail is an intrinsically disordered region and is a hot spot for post-translational modifications (particularly phosphorylation) and protein-protein interactions. Evolutionary analysis of PTEN and its interacting proteins revealed that the PTEN C-tail has only recently evolved to acquire the ability to engage in a myriad of protein-protein interactions, resulting in its versatile functions. Replacement of the PTEN C-tail serine/threonine residues with alanines generated an artificial mutant, PTEN-4A, which remained “phospho-deficient” and therefore constitutively active. Interestingly, PTEN-4A suppressed cell proliferation and migration to a greater extent than PTEN-WT. PTEN-4A preferentially localized to the nucleus where it suppressed E2F-mediated transcription of cell cycle genes. PTEN physically interacted with the E2F1 protein and at E2F1-binding sites on chromatin, a likely mechanism for its transcriptional function. Further, deletion analysis on various PTEN domains revealed that the C2 domain of PTEN is indispensable for suppression of E2F-related genes. Systematic transcriptional promoter-reporter assays identified disease-associated C2 domain mutations that lose their ability to suppress E2F-mediated transcription, supporting the concept that these mutations are oncogenic in patients. Consistent with my findings, I observed increased level of PTEN phosphorylation and reduced nuclear PTEN levels in lung cancer patient samples. Further, to determine whether the enhanced growth-suppressive properties of PTEN-4A may be due to differential protein-protein interactions, I performed a comparative proteomic profiling of PTEN-WT and PTEN-4A interactomes using the SILAC methodology. Galectin-1 was identified as a candidate protein that binds preferentially to PTEN-WT and inhibits its tumor suppressive function. Taken together, the various tumor suppressive mechanisms of PTEN-4A may be harnessed therapeutically as adjunctive cancer therapy. Use of small molecule inhibitors that hinder PTEN C-tail phosphorylation is a plausible approach to activate PTEN function to reduce tumor burden.

No description available.